Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret

Toxicology and Applied Pharmacology

Volumn 232, Issue 3, 2008, Pages 369-375

  Warneck, Julie B ^a   Cheng, Frankie H M ^b   Barnes, Matthew J ^a   Mills, John S ^a   Montana, John G ^a   Naylor, Robert J ^c   Ngan, Man P ^b   Wai, Man K ^b   Daiss, Jürgen O ^d   Tacke, Reinhold ^d   Rudd, John A ^b  

^a Takeda Cambridge Ltd   (United Kingdom)

^b Emesis Research Group   (Hong Kong)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

(R) sila venlafaxine; (R,R) reboxetine; (S,S) reboxetine; Acute; Antidepressant; Cisplatin; Delayed; Emesis; Reuptake

Indexed keywords

APOMORPHINE; CISPLATIN; DEXAMETHASONE; IPECAC; ONDANSETRON; REBOXETINE; SILAVENLAFAXINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FERRET; MALE; NONHUMAN; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; APOMORPHINE; CISPLATIN; CYCLOHEXANOLS; FERRETS; MALE; MORPHOLINES; SEROTONIN ANTAGONISTS; VOMITING;

MUSTELA;

EID: 53649085094     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.07.003     Document Type: Article

References (38)

1. Andrews P.L.R., and Rudd J.A. The role of tachykinins and the tachykinin receptor in nausea and emesis. In: Holzer P. (Ed). Handbook of Experimental Pharmacology (2004), Springer-Verlag Berlin Heidelberg, Germany 359-440
2. Beleslin D.B., and Strbac M. Noradrenaline-induced emesis. Alpha-2 adrenoceptor mediation in the area postrema. Neuropharmacology 26 (1987) 1157-1165
3. Bellg A.J., Morrow G.R., Barry M., Angel C., and DuBeshter B. Autonomic measures associated with chemotherapy-related nausea: techniques and issues. Cancer Invest. 13 (1995) 313-323
4. Charmandari E., Tsigos C., and Chrousos G. Endocrinology of the stress response. Ann. Rev. Physiol. 67 (2005) 259-284
5. Costall B., Domeney A.M., Naylor R.J., Owera-Atepo J.B., Rudd J.A., and Tattersall F.D. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 29 (1990) 453-462
6. Cubeddu L.X. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53 Suppl. 1 (1996) 18-25
7. Daiss J.O., Burschka C., Mills J.S., Montana J.G., Showell G.A., Warneck J.B.H., and Tacke R. Sila-venlafaxine, a sila-analogue of the serotonin/noradrenaline reuptake inhibitor venlafaxine: Synthesis, crystal structure analysis and pharmacological characterization. Organometallics 25 (2006) 1188-1198
8. Eisensamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., Bondy B., Parsons C., Gilling K., Zieglgänsberger W., Holsboer F., and Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol. Psychiat. 8 (2003) 994-1007
9. 3 receptors in raft-like domains. J. Neurosci. 25 (2005) 10198-10206
10. Fetting J.H., Stefanek M.E., Sheidler V.R., Elsworth J.D., Piantadosi S., and Roth R.H. Noradrenergic activity in anticipatory nausea. Psychosom. Med. 54 (1992) 641-647
11. Fleishaker J.C. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin. Pharmacokinet. 39 (2000) 413-427
12. Fredrikson M., Hursti T.J., Steineck G., Fürst C.J., Börjesson S., and Peterson C. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br. J. Cancer 70 (1994) 642-645
13. Fukunaka N., Sagae S., Kudo R., Endo T., Hirafuji M., and Minami M. Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Gen. Pharmacol. 31 (1998) 775-781
14. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clin. Ther. 25 (2003) 2138-2154
15. Hasegawa M., Sasaki T., Sadakane K., Tabuchi M., Takeda Y., Kimura M., and Fujii Y. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors. Jpn. J. Pharmacol. 89 (2002) 113-119
16. Hesketh P.J., Van Belle S., Aapro M., Tattersall F.D., Naylor R.J., Hargreaves R., Carides A.D., Evans J.K., and Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 39 (2003) 1074-1080
17. Hikasa Y., Akiba T., Iino Y., Matsukura M., Takase K., and Ogasawara S. Central α-adrenoceptor subtypes involved in the emetic pathway in cats. Eur. J. Pharmacol. 229 (1992) 241-251
18. Inoue S., Endo K., Endo K., Nakamura R., and Itou H. Relationship between neurotransmitter blood noradrenalin and nausea/emesis after chemotherapy for lung cancer. Jpn. J. Cancer Chemother. 33 (2006) 931-936
19. Japundzic-Zigon N., Samardzic R., and Beleslin D.B. Clonidine-induced emesis: a multitransmitter pathway concept. Pharmacol. Res. 35 (1997) 287-297
20. Khandker S.K., Mukerjee D., Gurtu S., Pant K.K., Dhawan K.N., and Sinha J.N. Modification of reserpine-induced emetic response in pigeons by α 2-adrenoceptors. Pharmacol. Res. 29 (1994) 383-387
21. Koriech O.M. Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin. Oncol. 7 (1995) 371-372
22. Langworth S., Bodlund O., and Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J. Clin. Psychopharmacol. 26 (2006) 121-127
23. Lau A.H., Ngan M.P., Rudd J.A., and Yew D.T. Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret. Eur. J. Pharmacol. 516 (2005) 247-252
24. Linnér L., Wiker C., Arborelius L., Schalling M., and Svensson T.H. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J. Neural. Transm. 111 (2004) 127-139
25. Matsumoto S., Kawasaki Y., Mikami M., Nakamoto M., Tokuyasu H., Kometani Y., Chikumi H., Hitsuda Y., Matsumoto Y., and Sasaki T. Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer. Jpn. J. Cancer Chemother. 26 (1999) 535-538
26. Morrow G.R., Angel C., and Dubeshter B. Autonomic changes during cancer chemotherapy induced nausea and emesis. Br. J. Cancer 66 Suppl. XIX (1992) S42-45
27. Naylor R.J., and Rudd J.A. Pharmacology of ondansetron. Eur. J. Anaesthesiol. 9 Suppl. 6 (1992) 3-10
28. Naylor R.J., and Rudd J.A. Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Oncology 53 Suppl. 1 (1996) 8-17
29. Okada F., Saito H., and Matsuki N. Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur. J. Pharmacol. 309 (1996) 33-35
30. Rey E., Dostert P., d'Athis P., Jannuzzo M.G., Poggesi I., and Olive G. Dose proportionality of reboxetine enantiomers in healthy male volunteers. Biopharm. Drug Dispos. 20 (1999) 177-181
31. Robichaud A., Savoie C., Stamatiou P.B., Tattersall F.D., and Chan C.C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40 (2001) 262-269
32. Rudd J.A., and Andrews P.L.R. Mechanisms of acute, delayed and anticipatory vomiting in cancer and cancer treatment. In: Hesketh P. (Ed). Management of Nausea and Vomiting in Cancer and Cancer Treatment (2004), Jones and Barlett Publishers Inc., New York 15-66
33. 3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33 (1994) 1607-1608
34. Rudd J.A., and Naylor R.J. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br. J. Pharmacol. 118 (1996) 209-214
35. Sam T.S., Chan S.W., Rudd J.A., and Yeung J.H. Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur. J. Pharmacol. 417 (2001) 231-237
36. Showell G.A., Barnes M.J., Daiss J.O., Mills J.S., Montana J.G., Tacke R., and Warneck J.B. (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorg. Med. Chem. Lett. 16 (2006) 2555-2558
37. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., and McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry 47 (2000) 818-829
38. Yazicioglu B., Akkaya C., Sarandol A., Akgoz S., Saygin Eker S., and Kirli S. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1271-1276